Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti-vascular endothelial growth factors: A comparison between two treatment regimens

Alessandro Invernizzi, Francesco Pichi, Richard Symes, Sophia Zagora, Aniruddha Kishandutt Agarwal, Phuc Nguyen, Stefano Erba, Alba Xhepa, Luca De Simone, Luca Cimino, Mark C. Gillies, Peter J. Mccluskey

Research output: Contribution to journalArticlepeer-review

Abstract

Background and aim: There is still no established treatment regimen for eyes with inflammatory choroidal neovascularisation (iCNV) treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections. This study compared the 24-month outcomes of two treatment regimens of anti-VEGF injections in eyes with iCNV. Methods: Eyes with iCNV treated with anti-VEGF injections were divided into two groups: Eyes treated with a loading phase of 3 monthly injections and then re-treated as needed (LOADING group) and eyes treated as needed from the beginning (PRN group). Visual acuity (VA), number of injections and iCNV recurrences at 24 months were compared between the groups. Results: Eighty-two eyes were included, 42 in the LOADING and 40 in the PRN group. Baseline VA (mean(SD)) was 72.3 (15.8) letters in the LOADING vs 75.7 (15.6) letters in the PRN group (p=0.32). The VA (mean (95% CI)) increased at 3 months (+14.8 (10.6 to 18.9) and +11.2 (6.4 to 16) letters in the LOADING and PRN group, respectively) and remained significantly higher than baseline over the entire follow-up in both groups (all p<0.001). At 24 months, there was no difference in VA between the LOADING and PRN group (87.8 (13.8) vs 90.3 (11.3) letters, p=0.36) but the LOADING group received significantly more injections (median (Q1-Q3)) than the PRN (4.5 (3-7) vs 2.5 (2-3.2), p<0.0001). The iCNV recurrences were similar in both groups. Conclusions: ICNV responded well to anti-VEGF with significant and sustained VA improvement. The loading phase did not confer any advantage in terms of outcomes. PRN regimen from the beginning was as effective as more intensive treatment.

Original languageEnglish
Article number315257
JournalBritish Journal of Ophthalmology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Keywords

  • aflibercept
  • anti-VEGF
  • bevacizumab
  • CNV
  • drugs
  • inflammation
  • inflammatory choroidal neovascularization
  • neovascularisation
  • ranibizumab
  • regimen
  • retina
  • treatment
  • uveitis

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti-vascular endothelial growth factors: A comparison between two treatment regimens'. Together they form a unique fingerprint.

Cite this